-
Phase 4
-
-
18+Age Range
-
Active, Not Recruiting
Menu
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Active, Not Recruiting
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Inclusion Criteria - Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. - Deemed by the investigator to be a candidate for phototherapy or systemic therapy. - ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1 - Dermatology Life Quality Index (DLQI) score > 5 at the Screening Visit and Day 1 - Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1 Exclusion Criteria: Target Disease Exceptions: - Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.
Study Arms
Experimental: Deucravacitinib
Study Arms
Placebo Comparator: Placebo then Deucravacitinib